Skip to main content

Mogamulizumab Side Effects

Medically reviewed by Drugs.com. Last updated on Dec 21, 2023.

Applies to mogamulizumab: intravenous solution.

Serious side effects of Mogamulizumab

Along with its needed effects, mogamulizumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking mogamulizumab:

More common

Less common

Rare

Incidence not known

Other side effects of Mogamulizumab

Some side effects of mogamulizumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to mogamulizumab: intravenous solution.

Hematologic

Very common (10% or more): Thrombocytopenia (14%), anemia (12%)[Ref]

Immunologic

Common (1% to 10%): Candidiasis, urinary tract infection, folliculitis, pneumonia, otitis, herpesvirus infection

Postmarketing reports: Hepatitis B virus reactivation[Ref]

Local

Very common (10% or more): Infusion reaction (33%)[Ref]

Musculoskeletal

Very common (10% or more): Musculoskeletal pain (e.g., back pain, bone pain, musculoskeletal chest pain, musculoskeletal pain, myalgia, neck pain, pain in extremity) (22%)

Common (1% to 10%): Muscle spasm[Ref]

Ocular

Common (1% to 10%): Conjunctivitis[Ref]

Metabolic

Very common (10% or more): Albumin decreased (34%), calcium decreased (30%), uric acid increased (29%), phosphate decreased (27%)

Common (1% to 10%): Hyperglycemia, hyperuricemia, hypomagnesemia, weight gain, weight loss, anorexia[Ref]

Psychiatric

Common (1% to 10%): Insomnia, depression[Ref]

Oncologic

Uncommon (0.1% to 1%): Tumor lysis syndrome

Respiratory

Very common (10% or more): Upper respiratory tract infection (e.g., laryngitis viral, nasopharyngitis, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, viral upper respiratory tract infection) (22%), cough (11%)

Common (1% to 10%): Dyspnea[Ref]

Other

Very common (10% or more): Fatigue (31%), pyrexia (17%), edema (16%)

Common (1% to 10%): Chills, fall[Ref]

General

The most common adverse reactions (reported in 20% or more of patients)

were rash (including drug eruption), infusion related reactions, fatigue, diarrhea, upper respiratory tract infection. and musculoskeletal pain. Adverse reactions reported in 10% or more of patients included skin infection, pyrexia, nausea,

edema, thrombocytopenia, headache, constipation, mucositis, anemia, cough, and hypertension.[Ref]

Nervous system

Very common (10% or more): Headache (14%)

Common (1% to 10%): Dizziness, peripheral neuropathy[Ref]

Renal

Common (1% to 10%): Renal insufficiency[Ref]

Cardiovascular

Very common (10% or more): Hypertension (10%)

Common (1% to 10%): Arrhythmia

Uncommon (0.1% to 1%): Myocardial infarction, myocardial infarction, cardiac failure

Postmarketing reports: Stress cardiomyopathy[Ref]

Dermatologic

Very common (10% or more): Rash (dermatitis [e.g., allergic, atopic, bullous, contact, exfoliative, infected); drug eruption [e.g., palmoplantar keratoderma]; rash [e.g., generalized, macular, maculopapular, papular, pruritic, pustular]; skin reaction [e.g., toxic skin eruption]) (35%), drug eruption (24%), skin infection (e.g., cellulitis, dermatitis infected, erysipelas, impetigo, infected skin ulcer, periorbital cellulitis, skin bacterial infection, skin infection, staphylococcal skin infection) (22%)

Common (1% to 10%): Xerosis, alopecia[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (28%), mucositis (e.g., aphthous stomatitis, mouth ulceration, mucosal inflammation, oral discomfort, oral pain, oropharyngeal pain, stomatitis) (17%), nausea (16%), constipation (13%)

Common (1% to 10%): Vomiting, abdominal pain[Ref]

Frequently asked questions

References

1. Product Information. Poteligeo (mogamulizumab). Kyowa Kirin, Inc. 2018.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.